<bill session="117" type="h" number="6963" updated="2023-03-08T19:58:48Z">
  <state datetime="2022-03-07">REFERRED</state>
  <status>
    <introduced datetime="2022-03-07"/>
  </status>
  <introduced datetime="2022-03-07"/>
  <titles>
    <title type="display">Accelerated Approval Integrity Act of 2022</title>
    <title type="short" as="introduced">Accelerated Approval Integrity Act of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for postapproval studies for drugs approved using accelerated approval, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="P000034"/>
  <cosponsors>
    <cosponsor bioguide_id="M000087" joined="2022-03-16"/>
  </cosponsors>
  <actions>
    <action datetime="2022-03-07">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-03-07" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-03-08">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-10-18T14:40:44Z" status="Introduced in House">Accelerated Approval Integrity Act of 2022

This bill establishes requirements relating to postapproval studies for drugs that receive accelerated approval for serious or life-threatening diseases or conditions, such as requiring product sponsors to agree in advance to conduct such studies and terminating product approval if certain benchmarks are not met.</summary>
</bill>
